Influenza's End Game? Cidara Unveils a Revolutionary Flu Shield
- Cidara Therapeutics (Nasdaq: CDTX) to spotlight CD388, a potential single-dose, universal flu preventative, in a pivotal R&D Day.
- World-renowned virology and pandemic experts to join the May 22, 2025, virtual event.
- Anticipation builds for updates on the 5,000-subject Phase 2b NAVIGATE trial and the future of flu protection.
SAN DIEGO – The age-old battle against influenza, a relentless foe that grips the globe season after season and threatens devastating pandemics, may be nearing a turning point. Cidara Therapeutics is poised to unveil the latest on CD388, an investigational drug with the audacious goal of providing universal, once-per-flu season protection against all known influenza strains1, 2.
On Thursday, May 22, 2025, from 10:00 AM ET, the company will host a virtual R&D Day, pulling back the curtain on a potential revolution in preventative medicine. This isn't just another flu shot. CD388, born from Cidara’s proprietary Cloudbreak® platform, is a drug-Fc conjugate (DFC) designed to directly inhibit viral proliferation, offering robust protection regardless of an individual's immune status – a critical advantage for the most vulnerable5, 6.
Joining Cidara’s management will be titans of the field: Dr. Frederick G. Hayden of the University of Virginia School of Medicine, a veteran in the development of seven approved influenza antivirals, and Dr. Rick Bright, former CEO of the Pandemic Prevention Institute at The Rockefeller Foundation and an international authority on pandemic preparedness2, 7.
The high-stakes discussion will dissect the 2024-2025 flu season, delve into the design and crucial anticipated statistical analysis plan for the recently enrolled Phase 2b NAVIGATE trial8, and outline the path towards Phase 3 studies. The commercial landscape and CD388's potential to neutralize pandemic threats will also take center stage. Could a single annual dose truly consign the dread of flu season to history? The world will be watching.
More information and registration details can be found on Cidara's official communications.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.